Suven Life Sciences allotted 1.86 Cr shares via warrant conversion, raising ₹248.84 Cr, significantly boosting its paid-up capital.

The company is also incorporating a Singapore subsidiary for biopharmaceutical clinical development, involving an investment of up to $100M.